Earnings Releases·Oct 28, 2026, 7:05 AM ET

Amarin Corporation plc — Q3 2026 Earnings Summary

Total net revenue declined 20% year-over-year to $39.6 million in Q3 2026, driven by a 30% drop in U.S. product revenue, though licensing and royalty revenue surged 139% to $2.7 million.
The company reported its first profitable quarter in over two years with a net income of $0.2 million, marking a significant improvement from a $7.7 million loss in Q3 2025, supported by a 44% reduction in operating expenses.
Cash reserves increased to $323.4 million as of September 30, 2026, with the company remaining debt-free and projecting cash balances of approximately $330 million by year-end.
Future outlook indicates stable U.S. volumes for the remainder of FY 2026 and continued sequential growth in global partner markets, with further operating expense reductions expected in Q4.
Strategic progress includes the launch of VAZKEPA in Poland's private pay market and positive clinical findings from the EMT2 trial suggesting potential new therapeutic applications for colorectal cancer liver metastases.